Figure 7

A2 and A3 treatment inhibits upregulation of inflammatory response genes in uninfected cells. (A) Schematic of peptide treatment in U87MG cells that are overlaid with supernatants from infected HMC3 cells to assess inflammation from bystander, peptide-treated cells (htp = hours post treatment; n = 1). (B) Fold change in PCR array gene expression in A2-treated sample as depicted by a heat map. Red (A7 and A12) represents expression of CCL16 and CCL22 genes. (C) Heat map of gene expression in A3-treated samples. Gene changes in array as follows; Red: CCL16, CCL22; Coral: CCR2, CXCL9; Orange: CCL23, CXCR1, IL3, IL9; Peach: CCL13, CCL3, CCL7, CCL8, CX3CR1, IL17A, IL9R, LTA; Beige = CCR3, CCR5, CCR6, CXCR2, FASLG, IFNA2, IL13, IL17C, IL21, TNFSF11, TNFSF13. Scale = Blue, decrease in gene expression; Red, increase in gene expression. (D)–(F) Decrease in expression levels of pro-inflammatory cytokines IL1α, IL1β, and TNF respectively in peptide treated cells. (G) and (H) Increase in the expression of anti-inflammatory genes IL1RN and IL7 respectively in peptide treated cells. (I) Increase in expression of genes involved in chemotaxis of leukocytes, CCL22 and CCL16, as a result of peptide treatment.